ANeuroTech
www.aneurotech.comANEUROTECH is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies.
Read more
ANEUROTECH is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies.
Read more
Employees statistics
View all employeesPotential Decision Makers
Chief Information Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(10)
Reach decision makers at ANeuroTech
Free credits every month!
ANeuroTech FAQ
Pharmaceutical Manufacturing
